Google
RIGL Stock Price & Analysis — Rigel Pharmaceuticals Inc (Healthcare >> Biotechnology)
RIGL FAQ
What is RIGL's P/E ratio?
Rigel Pharmaceuticals Inc (RIGL) currently trades at a P/E ratio of 1.90.
What is RIGL's ROE?
Rigel Pharmaceuticals Inc reports a Return on Equity (ROE) of 91.08%.
What is RIGL's dividend yield?
Rigel Pharmaceuticals Inc offers a dividend yield of 0.00%.
What is RIGL's Quality Score?
Our AI rates RIGL's overall financial quality at 92 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RIGL?
Our AI Timing Score for RIGL is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RIGL belong to?
Rigel Pharmaceuticals Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
RIGL AI Analysis Summary
Our AI summary for RIGL: Rigel Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 1.90, ROE of 91.08%, a dividend yield of 0.00%. Its financial Quality Score stands at 92/100 — fundamentals stronger than most of the market. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 38.70
Price
1.27
(3.39%)
Day Change
|
|
|---|
RIGL, the overall quality is excellent ( Quality = 92) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
Negative growth of ROE in the last year.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
73% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
30
GREAT
|
| Magic Formula Rank by ROE |
30
GREAT
|
| Magic Formula Rank by ROIC |
88
GOOD
|
| Price | 38.70 |
| PBV / Sector |
1.73 / 44,022.72
|
| Earning Per Share | 20.35 |
| PE / Sector |
1.90 / 19.17
GREAT
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
12.11 M
GREAT
|
| Average 1W Daily Value |
8.67 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
68% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-05 08:00:46 |
| Symbol | RIGL |
| Name | RIGEL PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 18.50 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 692.53 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
Phone: 650 624 1100
Website: https://www.rigel.com
Employees: 172
Sector: Healthcare >> Biotechnology
Description: Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap